SIGA Technologies Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY Revenue (est.)
$66.3Mnext fiscal year
FY EPS (est.)
$0.15next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Product Sales and Supportive Services Revenue Quarterly3.5M
Cash and Cash Equivalents Balance Quarterly145.6MTarget: Maintain strong liquidity to support capital returns and R&D
Watch Items
- Delivery of oral TPOXX to Asia Pacific customerTrigger: Q2 2026 delivery target of ~$13 millionAction: Monitor Q2 2026 financial results for revenue recognition of the Asia Pacific shipment.
- Delivery of IV TPOXX to the U.S. Strategic National Stockpile (SNS)Trigger: Q3 2026 delivery target of ~$26 millionAction: Verify completion of the $26 million procurement order under the 19C BARDA contract by the end of Q3 2026.
- European CHMP recommendation to withdraw mpox indication for TPOXXTrigger: Formal regulatory decision or label change by European authoritiesAction: Assess the impact on international commercialization efforts and potential changes to the European market strategy.
Research as of 19 Jun 2026